The nominal deal value is $12B. If consummated, this deal will create the second-largest global CRO, employing 35,000 people. (IQV is the largest.) A focus of the combined firm will be “virtual” clinical trials.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.